290A Stock Overview Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Chinook Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Chinook Therapeutics Historical stock prices Current Share Price US$36.40 52 Week High US$37.40 52 Week Low US$16.80 Beta 0.67 1 Month Change 3.41% 3 Month Change 75.00% 1 Year Change 89.58% 3 Year Change n/a 5 Year Change n/a Change since IPO 197.82%
Recent News & Updates Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index Aug 11 Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index
Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022) Aug 08
Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy Jul 29
Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress Jun 18 See more updates Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index Aug 11 Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index
Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022) Aug 08
Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy Jul 29
Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress Jun 18 Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.54 loss in 1Q 2022) May 11
Independent Lead Director recently sold €5.6m worth of stock Apr 21
Full year 2022 earnings released: US$2.87 loss per share (vs US$2.26 loss in FY 2021) Mar 01
Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer Feb 16
President recently sold €175k worth of stock Feb 03
Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021) Nov 12
Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022 Nov 04
Independent Director recently bought €212k worth of stock Sep 07
Second quarter 2022 earnings released: US$0.61 loss per share (vs US$0.97 loss in 2Q 2021) Aug 09
High number of new directors May 31
President recently bought €61k worth of stock May 28
Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022 May 21
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022 May 19
First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.88 loss in 1Q 2021) May 14
High number of new directors Apr 27
Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022 Apr 15
Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias Apr 13
High number of new directors Apr 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 19
Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022 Feb 01
High number of new directors Dec 06
President recently bought €101k worth of stock Aug 20
Sairopa B.V., entered into an agreement to acquire non-renal assets of Chinook Therapeutics, Inc. Aug 13 Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Growth Index
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress Jun 09
Chinook Therapeutics, Inc. announced delayed annual 10-K filing Mar 31
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Align Study of Atrasentan for Patients with Iga Nephropathy Mar 17
Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases Mar 03
Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Chk-336 for Treatment of Primary Hyperoxaluria Feb 03
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities Dec 10
President recently bought €53k worth of stock Nov 14
Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer Nov 11
Chinook Therapeutics, Inc. Provides Business Update Nov 07 Shareholder Returns 290A DE Biotechs DE Market 7D 0.6% 1.2% -0.3% 1Y 89.6% -14.3% 7.0%
See full shareholder returns
Return vs Market: 290A exceeded the German Market which returned 1.6% over the past year.
Price Volatility Is 290A's price volatile compared to industry and market? 290A volatility 290A Average Weekly Movement 20.0% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 290A's share price has been volatile over the past 3 months.
Volatility Over Time: 290A's weekly volatility has increased from 11% to 20% over the past year.
About the Company Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.
Show more Chinook Therapeutics, Inc. Fundamentals Summary How do Chinook Therapeutics's earnings and revenue compare to its market cap? 290A fundamental statistics Market cap €2.65b Earnings (TTM ) -€224.40m Revenue (TTM ) €5.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 290A income statement (TTM ) Revenue US$5.85m Cost of Revenue US$193.72m Gross Profit -US$187.87m Other Expenses US$57.79m Earnings -US$245.65m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -3.42 Gross Margin -3,211.95% Net Profit Margin -4,199.93% Debt/Equity Ratio 0%
How did 290A perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/08/11 17:26 End of Day Share Price 2023/08/10 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Chinook Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Antonia Borovina Bloom Burton & Co. Charles Duncan Cantor Fitzgerald & Co. Joshua Schimmer Evercore ISI
Show 8 more analysts 
